Literature DB >> 11590074

Characteristics of antitumour activity of cepharanthin against a human adenosquamous cell carcinoma cell line.

K Harada1, T Bando, H Yoshida, M Sato.   

Abstract

Cepharanthin is one of the biscoclaurine alkaloids widely used for treatment of many acute and chronic diseases; snakebite, bronchial asthma, alopecia areata, leukopenia during radiation therapy or anticancer treatment. Recently, it has been reported that cepharanthin exerts antitumour effects by increasing immunological competence of the host or apoptosis-inducing activity. In this study, we examined the antitumour effects of cepharanthin against a human adenosquamous cell carcinoma cell line (TYS). Treatment of TYS cells with cepharanthin (10 approximately 20 microg/ml) resulted in a significant suppression of cell growth. Moreover, it was found by the flow cytometry analysis, nick end labelling or agarose gel electrophoresis, that G1 arrest and DNA fragmentation occurred in cepharanthin-treated cells. In addition, it was detected that induction of p21(WAF1) protein and activation of caspase 3 protype, which is one of Interleukin-1beta converting enzyme (ICE) family proteases, were detected by Western blotting. The TYS tumour-bearing nude mice were treated with cepharanthin, which was administered subcutaneously (20 mg/kg/day). The cepharanthin treatment results in a significant suppression of tumour growth and an induction of apoptosis. These findings suggest that cepharanthin induces G1 arrest via expression of p21(WAF1) and apoptosis through caspase 3.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11590074     DOI: 10.1016/s1368-8375(00)00125-1

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  1 in total

1.  Interaction of cepharanthine with immobilized heat shock protein 90α (Hsp90α) and screening of Hsp90α inhibitors.

Authors:  Jun Haginaka; Tomoko Kitabatake; Iyo Hirose; Hisami Matsunaga; Ruin Moaddel
Journal:  Anal Biochem       Date:  2012-12-03       Impact factor: 3.365

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.